• The present diagnostic and treatment rates of osteoporosis 6 months after a fragility fracture [ Time Frame: June 2007 ] [ Designated as safety issue: No ]
  
• The osteoporosis diagnostic rate and on the osteoporosis pharmacological treatment rate 12 months after the educational interventions [ Time Frame: June 2007 ] [ Designated as safety issue: No ]
  
• The average 5-year, 10-year, 15-year, and 20-year probabilities of a fragility fracture by age, site of previous fragility fracture, and type of ROCQ intervention. [ Time Frame: July 2009 ] [ Designated as safety issue: No ]
  

• Changes of modifiable risk factors for osteoporosis 12 months after the intervention [ Time Frame: September 2009 ] [ Designated as safety issue: No ]
  
• Proportion of fragility versus traumatic fractures. [ Time Frame: June 2007 ] [ Designated as safety issue: No ]
  
• Health care resource utilization associated with specific types of fragility fracture and recurrent fractures. [ Time Frame: September 2010 ] [ Designated as safety issue: No ]
  
• Assess health utility index (EQ-5D) after a fragility fracture. [ Time Frame: September 2010 ] [ Designated as safety issue: No ]
  
• Satisfaction with the process of care before and after implementing ROCQ's interventions. [ Time Frame: June 2010 ] [ Designated as safety issue: No ]
  
• One-year mortality rate following a fragility fracture. [ Time Frame: May 2009 ] [ Designated as safety issue: No ]
  
• Persistence to pharmacological treatment 12 months after the intervention [ Time Frame: October 2009 ] [ Designated as safety issue: No ]
  
• Incidence of recurrent fracture and health care resources utilization between women who previously had a fragility fracture and those who had a traumatic fracture. [ Time Frame: November 2010 ] [ Designated as safety issue: No ]
  

ROCQ is a patient health-management programme and prospective cohort study. Within the ROCQ programme, educational interventions to improve osteoporosis management will be evaluated using a randomized-control design. The programme is composed of a promotional campaign, three main phases and a 20-year follow-up.

At phase 1, 0 to 16 weeks after the fracture, participants with fragility and traumatic fractures will be recruited and will be asked information regarding their fracture.

At phase 2, 6 to 8 months after the fracture, all participants will complete questionnaires to evaluate demographic and clinical features, risk factors for osteoporosis, co-morbidities, status of diagnosis and treatment, and the EQ-5D. The current medical management of osteoporosis (or the care gap in diagnosis and treatment) will be measured using this questionnaire at phase 2. Once the phase 2 questionnaire has been completed, Only participants with fragility fractures will be randomized to one of the three following educational intervention groups: 1) the Educational Video Group, 2) the Documentation Group, or 3) the Control Group.

At phase 3, 12 to 14 months after randomization, the effectiveness of the interventions will be assessed by re-administering the questionnaires to participants who experienced a fragility fracture at baseline. The questionnaires evaluate the status of diagnosis and treatment of osteoporosis, modifiable risk factors and the health-related quality of life (EQ-5D). The impact of the interventions on the participants will be assessed by comparing diagnosis and treatments rates in each intervention arm.

If the long-term viability of the programme is secured, participants with fragility and traumatic fractures will be followed for a maximum period of 20 years using specific encoded personal data contained in the RAMQ and Quebec's drug plan databases.